# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $25 to ...
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $30 price target.
Baird analyst Joel Beatty maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from ...
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.DAYBUE net product sales guidance in the range of ...
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate...
Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and maintains $19 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and maintains $37...